Bridgeway Capital Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Bridgeway Capital Management’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-201,600	Closed	-$35K	–	1502
2022 Q3	$35K	Buy	201,600 +75,000	+59%	+$76.5K	﹤0.01%	1366
2022 Q2	$76K	Sell	126,600 -160,000	-56%	-$153K	﹤0.01%	1253
2022 Q1	$378K	Hold	286,600	–	–	0.01%	1014
2021 Q4	$748K	Buy	286,600 +81,000	+39%	+$245K	0.01%	859
2021 Q3	$639K	Buy	205,600 +117,000	+132%	+$390K	0.01%	960
2021 Q2	$330K	Sell	88,600 -24,000	-21%	-$79.9K	0.01%	1190
2021 Q1	$390K	Sell	112,600 -15,000	-12%	-$60.9K	0.01%	1165
2020 Q4	$429K	Sell	127,600 -25,000	-16%	-$89.5K	0.01%	1004
2020 Q3	$536K	Hold	152,600	–	–	0.01%	862
2020 Q2	$702K	Sell	152,600 -30,900	-17%	-$137K	0.01%	764
2020 Q1	$607K	Buy	183,500 +9,100	+5%	+$41.6K	0.01%	699
2019 Q4	$1.07M	Buy	+174,400	New	+$718K	0.01%	722

Other funds holding PHAS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Bridgeway Capital Management's PHAS Position: Q4 2022 in Review

Bridgeway Capital Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 201,600 shares — an estimated $35K sold.

Bridgeway Capital Management first reported a position in PHAS in Q4 2019 and held it in 12 quarters. The position peaked at $1.07M in Q4 2019. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

Bridgeway Capital Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Bridgeway Capital Management sold 201,600 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $35K.
Bridgeway Capital Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 12 quarters.
Bridgeway Capital Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $1.07M in Q4 2019.
5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Bridgeway Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.